Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Ipsen Announces Data Presentation for Dysport® (abobotulinumtoxinA) at American Academy of Cerebral Palsy and Developmental Medicine

Posted on: 23 Sep 16

BASKING RIDGE, N.J., Sept. 21, 2016 /PRNewswire/ -- Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR:  IPSEY), today announced that an additional data analysis regarding the safety and efficacy of repeated treatment sessions of Dysport® (abobotulinumtoxinA) in children (aged 2 and older) with lower limb spasticity will be presented at the annual meeting of the American Academy of Cerebral Palsy and Developmental Medicine (AACPDM) being held in Hollywood, Florida, September 20 – 24, 2016.

The data will be shared in an oral presentation of the results of an open label extension of a multicenter, prospective, double-blind, randomized, placebo-controlled study assessing Dysport® in pediatric patients 2 to 17 years of age with lower limb spasticity because of cerebral palsy causing dynamic equinus foot deformity. Patients requiring retreatment at Week 12 through Week 28 (the last double-blind visit of the study) completed the study and were offered entry into the open label extension study to receive up to 4 additional treatment sessions.

"We are pleased to present this data at this year's AACPDM meeting, following the FDA's recent approval of Dysport® for the treatment of lower limb spasticity in pediatric patients aged two and older," said Cynthia Schwalm, EVP, North America Commercial Operations, Ipsen. "Ipsen is committed to fully exploring the role that Dysport® can play in helping meet the needs of children with lower limb spasticity."

Key presentation:

Safety and efficacy of repeated dosing of abobotulinumtoxinA (Dysport®) in children with lower limb spasticity due to cerebral palsy

Presenter: Dr. Mauricio Delgado, Director, Texas Scottish Rite Hospital

Abstract #156242: Oral presentation: September 22, 12:02 p.m. to 12:09 p.m., Diplomat Ballroom 4 + 5

About Dysport® (abobotulinumtoxinA) for Injection
Dysport® is an injectable form of botulinum toxin type A (BoNT-A), which is isolated and purified from Clostridium bacteria producing BoNT-A. It is supplied as a lyophilized powder.

The C.L.I.M.B.® (Continuum of Learning to Improve Management with Botulinum Toxin; injector training platform for Dysport® is a multi-tiered learning continuum designed to educate physicians with every level of experience. C.L.I.M.B.® can help physicians improve their clinical skills involving the appropriate use of Dysport®.

For more information:

Editor's Details

Mike Wood

Last updated on: 23/09/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.